Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06626230 · ClinicalTrials.gov registry record · Phase 1
Safety of Anal Curcumin
A Phase 1 study of Anal High-grade Squamous Intraepithelial Lesion, sponsored by Lisa Flowers.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT06626230: Recruiting Phase 1 study of Anal High-grade Squamous Intraepithelial Lesion, sponsored by Lisa Flowers.
NCT06626230 is a Phase 1 study of Anal High-grade Squamous Intraepithelial Lesion that is actively recruiting participants, run by Lisa Flowers. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06626230, a Phase 1 study of Anal High-grade Squamous Intraepithelial Lesion, is actively recruiting participants, sponsored by Lisa Flowers.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.
Primary Outcome
To determine the maximum tolerated dose (MTD) of curcumin, toxicities will be tabulated and reported per dose level according to grade and type of toxicity experienced. The dose level at which no more than 33% of study participants have a DLT will be considered the maximum tolerated dose.
Conditions Studied
Interventions
- DRUG Curcuminoid Capsules
Study Locations (2)
Georgia
- Grady Memorial Hospital - Atlanta
- Grady Hospital - Ponce De Leon Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
What NCT06626230 shows while recruiting
NCT06626230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Anal High-grade Squamous Intraepithelial Lesion appearing as the primary indexed condition, and to 1 intervention - of which Curcuminoid Capsules is the first listed.
NCT06626230 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06626230 about?
NCT06626230 is a clinical study titled "Safety of Anal Curcumin". The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgic...
What is the current status of trial NCT06626230?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-03-17. Estimated completion is 2026-01.
What conditions does trial NCT06626230 study?
This clinical trial studies the following conditions: Anal High-grade Squamous Intraepithelial Lesion.
What interventions are being tested in trial NCT06626230?
The interventions under investigation include: Curcuminoid Capsules (DRUG).
Who is sponsoring clinical trial NCT06626230?
This trial is sponsored by Lisa Flowers, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06626230 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal High-grade Squamous Intraepithelial Lesion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06626230's enrollment target sits among peer trials
48 1026th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI